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Abstract
Background: Omega-3 fatty acids are dietary essentials, and the current low intakes in most modern developed countries
are believed to contribute to a wide variety of physical and mental health problems. Evidence from clinical trials indicates
that dietary supplementation with long-chain omega-3 may improve child behavior and learning, although most previous
trials have involved children with neurodevelopmental disorders such as attention-deficit/hyperactivity disorder (ADHD) or
developmental coordination disorder (DCD). Here we investigated whether such benefits might extend to the general child
population.
Objectives: To determine the effects of dietary supplementation with the long-chain omega-3 docosahexaenoic acid (DHA)
on the reading, working memory, and behavior of healthy schoolchildren.
Design: Parallel group, fixed-dose, randomized, double-blind, placebo-controlled trial (RCT).
Setting: Mainstream primary schools in Oxfordshire, UK (n = 74).
Participants: Healthy children aged 7–9 years initially underperforming in reading (#33rd centile). 1376 invited, 362 met
study criteria.
Intervention: 600 mg/day DHA (from algal oil), or taste/color matched corn/soybean oil placebo.
Main Outcome Measures: Age-standardized measures of reading, working memory, and parent- and teacher-rated
behavior.
Results: ITT analyses showed no effect of DHA on reading in the full sample, but significant effects in the pre-planned
subgroup of 224 children whose initial reading performance was #20th centile (the target population in our original study
design). Parent-rated behavior problems (ADHD-type symptoms) were significantly reduced by active treatment, but little or
no effects were seen for either teacher-rated behaviour or working memory.
Conclusions: DHA supplementation appears to offer a safe and effective way to improve reading and behavior in healthy
but underperforming children from mainstream schools. Replication studies are clearly warranted, as such children are
known to be at risk of low educational and occupational outcomes in later life.
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Introduction
Omega-3 fatty acids are dietary essentials, but intakes are low by
historical standards in most modern developed countries [1]. The
longer-chain omega-3 found in fish, seafood and some algae –
known as docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) – are the most biologically important forms, not only for
cardiovascular and immune system health, but also for normal
development and functioning of the brain and nervous system [2].
Accumulating evidence from epidemiological, biochemical and
intervention studies suggests that low dietary intakes of these long-
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chain omega-3 may have a detrimental effect on children’s
behavior and cognitive development [3,4].
Prior to this study there was already some evidence from
randomized, controlled trials (RCTs) that dietary supplementation
with omega-3 long-chain, polyunsaturated fatty acids (LC-PUFAs)
may have benefits for child behavior and learning [5,6]. However,
almost all such studies had involved populations with specific
developmental conditions such as attention-deficit/hyperactivity
disorder (ADHD), dyslexia or developmental coordination disor-
der (DCD). They were also small trials with considerable
differences between the populations studied, treatment formula-
tions used, and outcomes assessed. Findings from these RCTs had
therefore been mixed, but the most consistently reported benefits
in children of school age had included improvements in attention
and concentration, and reductions in other ‘ADHD-type’ symp-
toms such as impulsive and oppositional behaviour, as well as
anxiety and emotional lability [5,6]. Highly significant improve-
ments in both reading and spelling performance were also found in
the one study that assessed these outcomes [7].
These findings raised the important question of whether such
results might have broader applicability. A systematic review of the
effects of omega-3 intake on child behavior and learning, carried
out in 2006 for the UK Food Standards Agency, emphasized that
findings from groups of children with varying levels of clinically
reported neurodevelopmental disorder could not reliably be used
to assess the potential effects of omega-3 fatty acids on the
educational performance of mainstream UK school children [8].
There was thus a clear need for RCTs involving healthy children
from the general school population. In designing such a study,
however, we reasoned that any benefits from omega-3 supple-
mentation would more likely be demonstrable in children who
were initially underperforming on the outcomes of interest.
Official figures show that 20% of all children in mainstream UK
schools are in need of additional learning support [9]. Given the
importance of literacy skills to children’s educational progress,
reading achievement was chosen as a primary outcome in this
study; and we decided to focus simply on those children whose
current reading performance placed them within the bottom 20%
of the general population distribution.
Treatment formulations were another important issue. Most
previous research had used varying mixtures of EPA and DHA
(the two main omega-3 LC-PUFAs found in fish oils) and
sometimes other ingredients, making it difficult to identify which
component(s) might be responsible for any treatment effects. DHA
is an essential structural component of neuronal membranes, and
therefore the main omega-3 found in brain and nerve tissue.
Furthermore, the ability of humans to synthesize DHA in-vivo
from shorter-chain, plant-derived omega-3 such as alpha-linolenic
acid, is very limited, making a direct dietary supply of DHA
particularly important [2].
This study was therefore designed to investigate the importance
of DHA for behavior and learning in healthy but underperforming
children from the mainstream school population. The study
outcomes were selected for their relevance to children’s educa-
tional progress and future life chances, and involved simple,
practical measures of reading, working memory and behavior.
(a) Reading: Literacy skills are fundamental to educational and
occupational success. Only 85 per cent of UK adults had a basic
level of functional literacy in 2005, and in 2006, five million adults
were judged to be under-functioning in this domain [10]. These
statistics are an issue of major public concern; and given the
dynamic and cumulative nature of the development of literacy
skills in children, early intervention is known to be more cost-
effective than later remediation [11].
(b) Working memory: The ability to hold and manipulate
information in the short-term is important for many aspects of
everyday life as well as educational performance; and furthermore,
working memory problems (particularly the accurate processing
and retrieval of auditory/verbal sequential information), are
commonly associated with reading difficulties [12,13]. (c) Behavior:
Difficulties with behavior in childhood are one of the best
predictors of poor educational and occupational achievements in
later life. Such problems affect an increasing proportion of UK
schoolchildren, and again early intervention is key to minimising
the adverse consequences to individuals, families and wider society
[14].
Objectives
To investigate the effects of dietary supplementation with
600 mg/day of the omega-3 LC-PUFA docosahexaenoic acid
(DHA) on children’s reading, working memory and behavior over
a 16-week period.
The hypothesis was that DHA would be of benefit in each of
these domains.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
This was a parallel group, fixed-dose, randomized, double-
blind, placebo-controlled trial (RCT).
Participants
The study was open to healthy children attending any
mainstream Oxfordshire primary school who were in the third,
fourth or fifth year-groups. Such children are typically aged 7–9
years, although a minority is aged 6 or 10 years.
As originally designed, the inclusion criteria required children to
be below the 20th centile on a age-standardized word reading test
normed on UK children [15]. In children within this age range,
this would typically equate to a reading performance of around 2
years below the level expected for the child’s chronological age.
Before first randomization, however, it became apparent that
planned study numbers would not be achieved unless this inclusion
criterion was relaxed to the 33rd centile (equivalent to reading at
around 18 months behind chronological age); hence, the protocol
was modified accordingly.
Children with specific medical disorders (e.g. visual or hearing
impairment), general learning difficulties, or who were taking
medications expected to affect behavior and learning, were
excluded from the study, as were those whose first language at
home was not English. Schools were also asked to exclude any
children whose social/family circumstances would have made
inclusion into the study inappropriate (e.g. serious illness in the
family). Children who, according to their parents, ate fish more
than twice a week or took omega-3 supplements were also
excluded.
The Oxfordshire Local Authority was an active partner in the
research, and they provided information on how children from
participating schools had performed on the national attainment
tests conducted on all 7 year olds in state schools in England,
Wales and Northern Ireland [16]. From this, an initial list was
drawn up of all children with below average attainment in reading
at that age. Teachers at participating schools were then invited to
modify this according to their opinions of the children’s current
reading performance. On this basis, letters were sent to parents
inviting their children to take part in the formal screening
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assessments, in which their reading ability was individually tested
to determine eligibility (see Figure 1).
Ethics
Written informed consent was gained from parents, and verbal
assent from the children, prior to the initial screening assessments.
The protocol for this trial and a CONSORT checklist are
included as supporting information. Ethical consent was gained
from the Milton Keynes Research Ethics Committee (08/H0603/
49).
Interventions
Children in the Active group received a fixed dose of 600 mg
DHA (from algal oil), delivered in three 500 mg capsules per day,
each providing 200 mg DHA. The Placebo treatment consisted of
three 500 mg capsules per day containing corn/soybean oil,
matched with the Active treatment for taste and color. Both
treatments were provided by Martek Biosciences Corporation
(now DSM Nutritional Lipids).
Schools were given a 16 week supply of capsules (labelled with
each participating child’s name) and asked to dispense 3 capsules
to all participating children once a day at lunch time during
school terms. Parents were also given a 16-week supply of
capsules and asked to dispense these to their children at
weekends, during school holidays and at any other time when
their children were not in school. Both schools and parents were
given full instructions for dispensing capsules and a diary to
record capsule consumption, aimed at both monitoring and
encouraging children’s compliance. Both schools and parents
were encouraged to telephone the research team at any time if
they had any concerns.
Figure 1. Flow of participants from invitation to randomization.
doi:10.1371/journal.pone.0043909.g001
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Outcomes
Primary outcomes, assessed at the baseline screening appoint-
ment for all children, and again at 16-week follow-up for the
children randomised, were as follows:
(a) Reading. This was assessed using the Word Reading
Achievement sub-test of the British Ability Scales (BAS II)
[15]. This is a widely used age-standardized, single word
reading test, normed on UK children, and sensitive enough
to show significant change over four months. Standardized
scores have a mean of 100 and a standard deviation of 15.
(b) Working memory. This was assessed via two further sub-
tests from the British Ability Scales: Recall of Digits Forward
and Recall of Digits Backward. Again, these measures are
age standardized, but use T-scores, which have a mean of 50
and a standard deviation of 10.
(c) Behavior. This was assessed by both teachers and parents
using the long versions of the Conners’ Rating Scales
(CTRS-L and CPRS-L) [17]. These are age-standardized,
highly valid and reliable scales, measuring child behavior
over several domains, expressed as T-scores (mean= 50,
sd = 10). They are symptom scales, thus for values above the
mean, higher scores indicate more severe difficulties with
behaviour and/or attention. For many years these scales
have been routinely used in medication trials for children
with behavior problems such as ADHD; and they have also
been used with success in several previous trials of omega-3
fatty acid supplementation.
Other measures
i) Demographic information. Information on eligibility for
free school meals (FSM) was provided by Local Authority data and
used as a proxy for Social Economic Status (SES) [18]. Local
Authority data were also used to report on participant ethnicity,
gender and age.
ii) Medication. Details were collected from parents/guard-
ians on current use of medication.
iii) Compliance. Compliance was assessed by counting the
capsules returned.
iv) Side effects. Side effects were recorded using the Barkley
Side Effects Rating Scale, a commonly-used instrument assessing
the frequency and severity of 17 common side effects which may
occur as the result of taking medication or supplements. Each
symptom is rated on a 10-point scale from absent to severe [19].
Description of Procedures
Baseline. Baseline assessments took place in schools during
normal school hours in a quiet room by two trained researchers.
Each child was assessed individually on reading and working
memory, and behavior questionnaires were given to the teachers
to complete. Parents were sent questionnaires by post.
Post-intervention. Children were re-assessed at school 16
weeks post-intervention, when all primary outcome measures were
repeated. Upon completion of the study, all participants were
given a three months’ supply of the Active supplement, as well as a
£5 gift token.
Sample size
Power calculations were performed based on the only previous
RCT to assess both reading ability and behavior in children [7].
The results indicated that 180 participants per group would
provide 90% power with an a of 5%, for an effect size of
r =20.169 (Cohen’s d =20.343).
Randomization
A statistician at the Centre for Statistics in Medicine in Oxford
independently performed the randomization. The program
included a minimization algorithm to ensure balanced allocation
of participants across the treatment groups for school (to control
for possible between-school differences) and sex (a potentially
important factor) [20]. Randomisation was performed only after
eligibility was assured, and it was concealed until after the initial
two-group analyses were complete.
Blinding
Investigators, participants and those assessing outcomes were all
blind to treatment allocation. Post-intervention, both teachers and
parents of participants were asked whether they thought their child
had been allocated to Active treatment or Placebo, and these
estimates were used to assess the maintenance of blinding.
Statistical methods
Group comparisons were carried out on primary outcomes
using change scores (i.e. the post-intervention score minus baseline
score), in line with previous studies. These were considered likely
to be more sensitive to treatment effects than total scores, given the
short intervention period of 16 weeks. Main analyses were
conducted on an intention-to-treat principle (ITT): thus, all
children were included according to treatment allocation,
irrespective of compliance with the intervention. Appropriate
checks were made that participants with missing data did not differ
significantly on any demographic variables. Missing data were
imputed using median values by treatment group. For all primary
outcomes, additional planned group comparisons were carried out
on the subgroup of children whose baseline reading scores were
#20th centile (based on the original protocol), and also on those
#10th centile (to evaluate any possible trends related to the severity
of initial reading problems).
As recommended for the credibility of subgroup analyses [21],
tests of interaction were also carried out to assess potential
differences in treatment efficacy between the two main subgroups,
i.e. all children with initial reading #20th centile and those
children with milder degrees of initial reading impairment.
For any measures with more than 15% missing data, additional
per-protocol analyses were conducted i.e. including only those
participants with complete data.
Results
Recruitment
Recruitment was carried out in 74 Oxfordshire mainstream
primary schools beginning in January 2009 and finishing in
November 2010. Post-intervention assessments (16 weeks after
enrolment) were completed in April 2011. Of the 1376 children
who were invited, 675 of their parents/guardians gave consent and
their children were assessed. Of these, 362 met study inclusion
criteria and were randomized. The most common reasons for
exclusion were that their reading exceeded the 33rd centile
(n = 236), followed by eating fish more than twice a week (n= 50);
other reasons for exclusion are described in the flowchart of
participants (n = 27) detailed in Figure 1.
Follow-up
Of the 362 children randomized, 359 were assessed again after
the 16-week intervention (179 Active, 180 Placebo). Three
children were lost at follow up (1 in the Active group, 2 in the
Placebo group). In addition, one child from the Placebo group
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failed to complete the Recall of Digits assessment at the post-
intervention follow-up.
Baseline data
The two treatment groups did not differ on any of the core
demographic variables, nor on any of the primary outcome
measures at baseline. Demographic information is provided in
Table 1. The mean age of the sample was 8 years 8 months, 53%
were male, 91% were white, and just over 20% were eligible for
free school meals (our proxy for low socio-economic status).
Baseline data on the primary outcomes are shown in Table 2.
With respect to these, mean reading performance of the children
randomized was 1.5 sd below normal, equating to a reading
performance around 18 months below chronological age. Working
memory scores were around 0.5 to 1 sd below population norms as
derived from the British Ability Scales II [15]. On the behavior
measures (where higher scores indicate greater difficulties), both
teacher and parent ratings were all within the normal range, with
the exception of the ‘cognitive problems’ sub-scale (assessing
attentional and related difficulties), where these children scored 1
sd above population means. A few other scales showed slight
elevations (.+0.5 sd), including ‘oppositional’ (both parents and
teachers), ‘anxious-shy’ (teacher ratings only) and both ‘social
problems’ and ‘psychosomatic’ (parent ratings only).
Did blinding work?
Parent and teacher estimates of group allocation at post-
intervention were used to assess the maintenance of blinding.
Group comparisons carried out on these estimates showed there
were no significant differences between groups, as shown in
Table 3.
Numbers analyzed
Intention-to-treat analyses were carried out on all children
randomized (n = 362) and on the pre-planned sub-groups defined
by baseline reading #20th and 10th centiles (n = 224 and n= 105
respectively) in line with the original protocol. Behavior ratings
were the only measures with .15% of the data missing (change
scores n = 273 for Teachers, and n= 246 for Parents), so additional
per protocol analyses were conducted on these measures.
Outcomes
a) Reading. Standardized reading score data are shown in
Table 4, and changes on this measure, which were the primary
outcome, are illustrated in Figure 2. The same data expressed as
‘reading ages’ are shown in Table 5.
Over the 16-week treatment period, very slight improvements in
reading were found over and above the gains that would be
expected during this time period. For all children randomized
(n = 362), the changes in standardized reading scores did not differ
by treatment group (Active mean= 1.5, sd = 4.4; Placebo
mean= 1.2, sd = 4.3). However, the planned analyses for pre-
defined sub-groups of poorer readers did show significant effects of
treatment on reading change. For children with baseline reading
#20th centile (n = 224), improvements were greater for active
treatment (Active mean= 2.0, sd = 4.2; Placebo mean=0.9,
sd = 3.9, p,0.04); and for those with baseline reading #10th
centile (n = 105), the treatment effect was slightly greater (Active
mean= 3.1, sd = 4.4; Placebo mean= 0.9, sd = 4.2, p,0.01).
The subgroup analysis was undertaken with an interaction effect
of DHA supplementation on reading with the primary sub-group,
i.e. those with initial reading #20th centile (n = 224). The
interaction effect was significant and positive (Interaction:
treatment*sub-group 2.152, p,=0.05; OLS regression with main
effects included (treatment and subgroup)). Therefore the treat-
ment effect in the #20th centile group can be said to be robust
[22].
b) Working memory. Data on these measures are provided
in Table 6. Post-intervention, standardized scores on Recall of
Digits Forward improved slightly in the sample as a whole (mean
change score = 1.4, sd = 6.0) whereas there was no change in
Recall of Digits Backward (mean change score = 0.0, sd = 7.3). In
each case there were no significant group differences on the
primary outcome of change scores, although post-intervention
scores on Recall of Digits Forward were higher in the active
treatment group as a whole (Active mean=42.6, sd = 8.4, Placebo
mean=41.2, sd = 7.7, p,0.04).
There were no significant effects of treatment on the working
memory change scores in the pre-planned sub-groups with
baseline reading #20th or 10th centiles. There was, however, a
suggestion that the slight group difference in favor of active
treatment increased with the degree of reading impairment, as
illustrated in Figures 3 and 4.
c) Behavior – Parent and Teacher ratings. For the sample
as a whole, behavior ratings from parents were lower post-
intervention than at baseline for almost all scales, as shown in
Table 7 (ITT) and Table 8 (per protocol) Teacher ratings,
however, showed minimal changes over the 16-week treatment
period, as shown in Table 9 (ITT) and Table 10 (per protocol).
Parent-rated behavior
The ITT analyses showed that behavioral improvements as
rated by parents were greater for Active treatment over Placebo on
six of the seven CPRS-L Global scales (Table 7). Their means (sds)
were as follows: ADHD Index (Active 24.5 (8.9), Placebo 22.6
(7.4), p,0.04), Restless-Impulsive (Active24.8 (8.6), Placebo22.3
(8.2), p,0.01), Emotional Lability (Active 23.1 (9.5), Placebo
20.2 (9.3), p,0.01), Global Index Total (Active 24.3 (8.8),
Placebo 21.8 (8.2), p,0.01), DSM-IV Hyperactive-Impulsive
(Active 23.8 (8.3), Placebo 22.2 (8.2), p,0.02), and DSM IV
Total (Active 23.8 (8.1), Placebo 22.1 (7.4), p,0.03). Significant
differences in favor of Active treatment were also found for two of
the seven CPRS-L sub-scales: Oppositional (Active 23.2 (10.1),
Placebo 20.4 (8.1), p,0.01), and Hyperactivity (Active 22.9 (7.2),
Placebo 21.2 (7.1), p,0.01).
In the per protocol analyses (n = 247), a similar pattern of results
was found (Table 8), although differences reached statistical
significance only for Anxiety (Active 24.1 (8.5), Placebo22.0 (7.7,
p =,0.05), Global Restless-Impulsive (Active 24.1 (7.5), Placebo
22.2 (6.8), p,0.02), Global Emotional Lability (Active 22.4 (7.7),
Placebo 21.0 (8.3), p,0.03) and Global Index Total (Active 23.8
(7.1), Placebo 22.0 (6.8) p,0.02).
No significant effects of treatment were found within the sub-
groups defined by severity of reading impairment at baseline.
(These data are not shown, but can be provided on request).
Teacher-rated behavior
The ITT analyses showed no significant differences in behavior
change scores between Active and Placebo groups on any of the
CTRS-L sub-scales or global scales, with the exception of the
‘Perfectionism’ sub-scale, on which both groups scored below the
normal population mean at baseline and post-intervention. (Active
mean=0.2, sd = 6.5, Placebo mean=20.8, sd = 7.4, p,0.03). In
the per protocol analyses (n = 273), no group differences were
significant.
No significant effects of treatment on teacher-rated behavior
change were found in the sub-groups defined by severity of
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reading impairment at baseline. (These data are not shown, but
can be provided on request).
Adverse events
The DHA supplement used is generally regarded as safe
(GRAS) and so no stopping guidelines were put in place except in
the case of serious adverse events. As expected, there were none in
the course of this trial. The parents of three children reported
minor adverse events during the intervention period and so they
discontinued treatment, but no unblinding was required. The
adverse events were: asthma symptoms (Active), nettle rash
(Placebo) and disruptive behavior (Active). The parent of one
child in the Active group reported hair loss 6 weeks after
completing the study.
Reported side effects. No group differences were found for
16 of the 17 potential side effects assessed by the Barkley scale.
However, children in the Placebo group (n = 146) were reported to
have more insomnia or trouble sleeping than those taking the
Active supplement (n = 140). Means (sds) for this item were 1.4
(2.2) and 1.0 (2.0) respectively (p =,0.03).
Compliance
Counts of capsules returned by schools indicated mean
compliance of approximately 75% and this did not differ between
Active (n = 138) and Placebo groups (n = 157). (From 200 capsules
allocated to schools for each child, quantities returned were: Active
mean= 50.0, sd = 51.8) and Placebo Mean= 42.0, sd = 39.5). Of
the 50 capsules allocated to parents for non-school days, more
than 50% of data were missing and so these are not reported.
Discussion
In this randomized controlled trial we investigated the effects of
dietary supplementation for 16 weeks with 600 mg/day of the
omega-3 fatty acid DHA or placebo in 362 healthy school children
mainly aged 7–9 years who were initially underperforming in
reading (#33rd centile). Our primary outcomes were reading,
working memory, and behavior (ADHD-type symptoms) as rated
by both parents and teachers, all of which are known to be
important for children’s future educational and occupational
achievement.
Outcomes
(a) Reading. The effects of DHA on children’s reading
progress were found to vary with their initial reading performance.
No treatment effect was found in the sample as a whole (selected
for initial reading #33rd centile). However, small but significant
benefits from DHA supplementation were seen in the 224 children
whose initial reading performance was #20th centile, (the target
population in our original study design), and these benefits were
more pronounced in those children whose initial reading
performance was #10th centile.
The practical implications of these findings are best illustrated
by the reading age scores (derived from the same data as the age-
standardized reading scores, and shown in Table 5). In children
with initial reading performance #20th centile, active treatment
was associated with an additional 0.8 months mean increase in
reading age change scores compared with placebo, while in those
initially reading #10th centile, the additional reading age gain from
treatment was 1.9 months. As reading ages would typically be
expected to increase by 4 months over the 16-week treatment
period, this means that the gains from DHA supplementation in
these sub-groups of poorer readers were around 20% and 50%
greater, respectively, than would normally be expected, helping
these children to catch up with their peer group.
Only two previous studies of omega-3 supplementation in UK
children have involved reading as an outcome measure. In an
unselected sample of typically developing children aged 8–10 years
who were reading normally for their age, no treatment effects were
found [23]. By contrast, highly significant benefits were found in
children with Developmental Coordination Disorder, whose
reading performance was initially well below the level expected
for their age [7]. Our results are broadly compatible with both
these findings, in that we only found benefits for reading in those
children whose initial performance was at or below the 20th
centile. Recently, a small study from Australia found no overall
treatment effect of omega-3 on reading, although this trial was
small and underpowered, and involved children selected for
ADHD symptoms [24]. Significant correlations were found,
Table 1. Demographic Information.
Whole group (n=362) Active (n=180) Placebo (n =182)
Age in months, mean (sd) 104.3 (10.1) 103.7 (10.0) 104.8 (10.1)
Sex, n (%)
Male 192 (53.0) 96 (53.3) 96 (52.7)
Female 170 (47.0) 84 (46.7) 86 (47.3)
Ethnicity, n (%)
White 330 (91.2) 163 (90.6) 167 (91.8)
Mixed 16 (4.4) 8 (4.4) 8 (4.4)
Other 7 (1.9) 3 (1.7) 4 (2.2)
Asian 2 (0.6) 2 (1.1) 0 (0.0)
Black 1 (0.3) 0 (0.0) 1 (0.5)
Unknown 6 (1.7) 4 (2.2) 2 (1.1)
Eligibility for free school meals, n (%)
Not eligible 289 (79.8) 144 (80.0) 145 (79.7)
Eligible 73 (20.2) 36 (20.0) 37 (20.3)
doi:10.1371/journal.pone.0043909.t001
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however, between increases in blood DHA and improvements in
reading; and these associations were more pronounced in the
subgroup who also had reading difficulties.
(b) Working Memory. Group differences did not reach
significance for the primary outcome of change scores on the
working memory measures (Recall of Digits Forward and
Backward), although the mean scores post-intervention for
children receiving DHA were significantly higher on Recall of
Digits Forward (tapping auditory sequential verbal memory).
The children in this study were not selected for working
memory problems, but their initial scores on these measures were
found to be 0.5–1 sd below population norms (consistent with the
Table 2. Primary Outcomes at Baseline, means (sd).
Whole sample (n =362) Active (n =180) Placebo (n=182)
READING*
Word Reading – Standard Score (sd)1 84.7 (6.3) 84.6 (6.6) 84.8 (6.7)
Reading age, months (sd) 86.6 (9.9) 86.1 (10.0) 87.1 (9.7)
WORKING MEMORY
Digits Forward – T-Scores{(sd) 40.5 (8.0) 41.0 (8.2) 40.0(7.7)
Digits Backward – T-scores{(sd) 44.0 (6.8) 44.0 (6.4) 44.0 (7.1)
BEHAVIOR
Teacher rated{ Sub-scales (T-scores){ Whole sample (n =329) Active (n =158) Placebo (n=171)
Oppositional 55.5 (13.4) 54.5 (12.6) 56.3 (14.2)
Cognitive Problems 61.6 (9.3) 61.8 (9.8) 61.5 (8.9)
Hyperactivity 53.4 (10.9) 53.4 (11.0) 53.4 (10.8)
Anxiety 57.4 (12.4) 57.2 (11.3) 57.7 (13.3)
Perfectionism 48.2 (8.3) 48.6 (8.9) 47.8 (7.8)
Social Problems 54.1 (11.0) 53.7 (10.8) 54.3 (11.2)
Global scales (T-scores){
ADHD Index 56.0 (11.0) 56.1 (11.5) 56.0 (10.5)
Global Restless-Impulsive 55.9 (11.3) 56.1 (11.8) 55.8 (10.7)
Global Emotional Lability 53.7 (12.7) 53.0 (11.5) 54.3 (13.7)
Global Index Total 55.8 (11.8) 55.6 (11.9) 56.0 (11.7)
DSM-IV Inattentive 58.1 (10.2) 57.8 (10.5) 58.4 (9.8)
DSM-IV Hyperactive-Impulsive 52.5 (10.9) 52.8 (11.4) 52.2 (10.5)
DSM-IV Total 56.2 (10.1) 56.1 (10.6) 56.3 (9.7)
Parent rated{{ Sub-scales (T-scores){ Whole sample (n =295) Active (n =148) Placebo (n=147)
Oppositional 56.9 (12.0) 58.0 (13.2) 55.8 (10.6)
Cognitive Problems 59.2 (11.1) 60.3 (11.4) 58.1 (10.7)
Hyperactivity 54.3 (9.8) 54.6 (9.8) 54.0 (9.9)
Anxiety 52.2 (10.4) 52.2 (11.0) 52.1 (9.9)
Perfectionism 48.9 (9.2) 48.4 (9.2) 49.3 (9.2)
Social Problems 56.2 (12.2) 56.7 (12.7) 55.7 (11.8)
Psychosomatic 55.6 (12.3) 54.7 (11.8) 56.5 (12.7)
Global scales (T-scores){
ADHD Index 57.7 (11.3) 58.6 (11.8) 56.8 (10.8)
Global Restless-Impulsive 56.8 (10.8) 57.7 (11.1) 56.0 (10.5)
Global Emotional Lability 54.4 (11.8) 55.3 (12.4) 53.4 (11.0)
Global Index Total 56.7 (11.1) 57.6 (11.5) 55.8 (10.7)
DSM-IV Inattentive 56.1 (10.8) 57.1 (11.2) 55.1 (10.4)
DSM-IV Hyperactive-Impulsive 57.2 (11.5) 57.6 (11.5) 56.8 (11.6)
DSM-IV Total 57.1 (10.9) 57.9 (11.3) 56.3 (10.5)
*Obtained from the British Ability Scales II.13
{Obtained from Conners’ Teacher Rating Scale (CTRS-L).15
{{Obtained from Conners’ Parent Rating Scale (CPRS-P).15
1Standard Scores have a mean of 100, sd = 15.
{Standard Scores have a mean of 50 sd = 10. For values above the mean, higher scores indicate more severe difficulties with behaviour and/or attention.
doi:10.1371/journal.pone.0043909.t002
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importance of working memory in the development of reading
skills). Thus there was some room for improvement on these
measures in our sample. This was not the case in the only other
RCT of mainstream schoolchildren to investigate omega-3 for
working memory, which found no effects of supplementation using
similar measures [23]. In the present study, the subgroup analyses
suggested that any improvements in working memory might be
greater in children with poorer initial reading performance, but
further studies would be need to explore this possibility.
(c) Behavior. Parent ratings of the children’s behavior
showed significant reductions on most symptom scales at the 16-
week follow-up, i.e. there was a significant placebo effect. Despite
this, the ITT analyses showed significant effects of DHA over
placebo for the sample as a whole on 8 of the 14 scales, assessing a
range of ADHD-type symptoms. These included sub-scales
assessing hyperactivity and oppositional behaviour, and global
scales tapping emotional lability (mood swings) and restless-
impulsive behaviour as well as total ADHD-type symptoms. These
findings are in keeping with those from previous trials of omega-3
LC-PUFA supplementation in children with various developmen-
tal disorders of behavior and learning [25,26] it is notable that
similar effects were found here in normal healthy children, even
though their behavioral problems pre-treatment were within the
normal population range.
By contrast, teachers’ ratings of the children’s behavior showed
minimal changes during the 16-week treatment period, and no
differences between treatment groups. Disparities between teacher
and parent ratings of child behavior are extremely common (which
is why a formal clinical diagnosis of ADHD requires consistency
across different settings). It is perhaps unsurprising that parents
might be more sensitive than teachers or other professionals to any
changes in their child’s behavior over a short intervention period,
as this has been found in controlled studies of other nutritional
interventions for child behaviour [27] as well as in other trials of
omega-3 supplementation [26]. However, teacher ratings have
proved sensitive to behavioral change in some of the previous
studies of omega-3 for ADHD-type symptoms in children [7,23].
Table 3. Maintenance of Blinding for Parents and Teachers, n (%).
Actual Treatment Allocation
Active Placebo
‘‘Guessed’’ treatment allocation Parent (n =135) Teacher (n =140) Parent (n =145) Teacher (n =136)
Placebo 87 (64.4%) 85 (60.7%) 87 (60.0%) 84 (61.8%)
Active 45 (33.3%) 51 (36.5%) 55 (37.9%) 49 (36.0%)
Don’t know 3 (2.2%) 4 (2.9%) 3 (2.1%) 3 (2.3%)
All values non-significant for Active versus Placebo using x2 test.
doi:10.1371/journal.pone.0043909.t003
Figure 2. Change in reading scores between baseline and post-intervention.
doi:10.1371/journal.pone.0043909.g002
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It is possible that missing data from parent ratings in our current
study could have introduced an element of positive bias, but we
think this unlikely. The findings are in line with the accumulating
evidence that supplementation with omega-3 is of modest benefit
in reducing ADHD-type symptoms in children [6,28]. They also
broaden this evidence from clinical groups with varying types of
developmental disorders, and other children whose behavioral
problems are above average, to healthy children whose behavioral
problems fall within the normal population range.
Generalizability
The context in which this trial was carried out was mainstream
UK schools, where the influence of the researchers was low and
contact with parents was indirect and minimal, whereas most
previous trials have involved children with specific behavioral
and/or learning difficulties recruited either from clinics or from
direct advertisement to parents. This classifies it as an ‘‘effective-
ness’’ - i.e. ‘real-world’ study - rather than an ‘‘efficacy’’ study, and
provides reasonable grounds to trust the generalizability of these
data to other mainstream school populations, albeit with some
caveats.
Generalizability to all children aged 7–9 years attending
mainstream UK schools is clearly limited, as our sample was
pre-selected for underperformance in reading. In terms of
socioeconomic status, the children in this study were fairly
representative of the general population of England, as the
percentage receiving free school meals was comparable to national
figures (20.2% vs 18.6%). However, ethnic minorities were under-
represented (91.2% were white, compared with 77.7% nationally),
primarily because our study required that children use English as
their first language at home. The percentage of boys was also
slightly elevated (53% vs 51% nationally), reflecting the fact that in
this age range, boys are typically more likely than girls to be
underperforming in reading.
Implications for Research and Practice
Various implementation issues concerning dose and formula-
tion, delivery and uptake may have a bearing on these results and
therefore merit brief consideration.
The dose we selected (600 mg/day) was comparable to those
used in most other trials of long-chain omega-3 for child behavior
and/or learning to date [6], and only slightly higher than the
intake of 500 mg/day recommended for general cardiovascular
health in adults by leading scientists in the field [29]. Higher doses
might possibly yield more substantial treatment effects, but this
would need to be investigated via systematic dose-ranging studies,
because intakes of individual nutrients may not relate in any
simple linear fashion to health or performance outcomes [30].
The formulation we used provided only DHA, whereas most
previous studies have used varying combinations of DHA, EPA
and sometimes other fatty acids. A recent meta-analysis found that
treatment effects on ADHD-type symptoms increased with the
proportion of EPA (and thus decreased with the proportion of
DHA) in the supplements used [6]. This analysis was based on
only 10 small and highly heterogeneous trials, however, and direct
comparisons would be needed to evaluate the relative merits of
different formulations with any degree of certainty.
The efficiency of delivery and uptake can also influence results
in any intervention study. The supplements were provided to
children on school days by a range of different staff at the 74
schools involved. Counts of capsules returned from schools
suggested that satisfactory compliance with the treatment was
Table 4. Standardized* Reading Scores, means (sd).
Baseline Post-Intervention Change Scores
Active Placebo P Active Placebo P Active Placebo P
All randomized (n=362) 84.6 (6.6) 84.8 (6.1) 0.937 86.1 (7.0) 86.0 (7.5) 0.895 1.5 (4.4) 1.2 (4.3) 0.279
Reading #20th Centile
(n=224)
80.6 (5.3) 81.2 (4.8) 0.582 82.6 (6.0) 82.1 (6.1) 0.708 2.0 (4.2) 0.9 (3.9) 0.041
Reading #10th Centile
(n=105)
75.6 (4.0) 77.5 (3.9) 0.006 78.7 (5.5) 78.4 (5.8) 0.862 3.1 (4.4) 0.9 (4.2) 0.011
*Standardized scores have a mean of 100, sd = 15.
Reading standard scores are derived from the British Ability Scales II.13
doi:10.1371/journal.pone.0043909.t004
Table 5. Reading Age* and Chronological age (in months), means (sd).
Baseline Post-Intervention Change scores
Active Placebo P Active Placebo P Active Placebo P
All randomized (n=362) 86.1 (10.0) 87.1 (9.7) 0.331 90.8 (10.1) 91.9 (10.9) 0.307 4.7 (4.7) 4.8 (4.6) 0.856
Chronological age 103.7 (10.0) 104.8 (10.1)
Reading #20th Centile (n=224) 82.5 (9.1) 84.1 (8.6) 0.173 87.4 (9.0) 88.3 (9.4) 0.288 4.9 (4.7) 4.1 (4.0) 0.239
Chronological age 104.6 (9.5) 106.1 (9.8)
Reading #10th Centile (n=105) 77.3 (7.3) 80.8 (7.9) 0.019 83.0 (7.0) 84.7 (8.8) 0.126 5.7 (4.8) 3.8 (4.1) 0.032
Chronological age 104.8 (9.0) 107.1 (9.8)
*Reading ages are derived from the British Ability Scales II.13
doi:10.1371/journal.pone.0043909.t005
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achieved in these settings, but these data were not complete.
Similarly, the parents who gave the children their supplies during
weekends and other non-school days will have varied in their
motivation and adherence to the treatment schedule; compliance
data here were unfortunately impossible to obtain, in line with
other studies.
This study provides the first evidence that dietary supplemen-
tation with the omega-3 DHA might improve both the behavior
and the learning of healthy children from the general school
population. The supplement was found to be safe and well
tolerated, as expected. The benefits we found for reading were
only evident amongst those children whose initial reading
performance fell within the lowest 20% of the normal distribution,
suggesting that for this particular outcome measure, DHA
supplementation should be regarded as a targeted intervention
for the poorest readers rather than a universal one. For behavior,
however, it is possible that the benefits may have broader
applicability, as reductions in parents’ ratings of ADHD-type
symptoms were evident across the entire sample studied here,
despite the relatively mild nature of these children’s initial
behavior problems. The current results thus extend the previous
findings in this area from clinically-defined groups to healthy but
underperforming children from the general school population, and
suggest that dietary deficiencies of DHA might have subtle
behavioral effects on children in general, as has been shown for
some combinations of artificial food additives [31].
Dietary intakes of long-chain omega-3 in modern western-type
diets are widely acknowledged to be sub-optimal, both for general
physical health and for mental health and performance [32].
Similarly, the importance of early intervention for behavior and
literacy problems in children is widely acknowledged to be more
effective and less costly than interventions later in life, by which
Table 6. Standardized Working Memory Scores (Recall of Digits Forward and Backward){, means (sd).
Baseline T Score (sd) Post-Intervention T Score (sd) Change Scores, T Score (sd)
Active Placebo P Active Placebo P Active Placebo P
RECALL OF DIGITS FORWARD
All randomized (n =362) 41.0 (8.2) 40.0 (7.7) 0.174 42.6 (8.4) 41.2 (7.7) 0.037 1.6 (6.2) 1.2 (5.7) 0.419
Reading #20th Centile (n=224) 39.8 (8.0) 39.9 (8.6) 0.812 41.9 (8.5) 40.5 (8.0) 0.104 2.0(6.8) 0.7 (5.6) 0.069
Reading #10th Centile (n=105) 39.4 (7.3) 39.1 (9.9) 0.607 41.9 (8.0) 40.2 (9.3) 0.132 2.5 (7.2) 1.1 (6.0) 0.247
RECALL OF DIGITS BACKWARD
All randomized(n =362) 44.0 (6.4) 44.0 (7.1) 0.767 44.3 (7.1) 43.7 (7.0) 0.621 0.4 (7.3) 20.3 (7.4) 0.204
Reading #20th Centile (n=224) 43.7 (6.1) 43.5 (7.5) 0.841 44.3 (7.0) 42.8 (7.7) 0.396 0.6 (6.8) 20.7 (7.3) 0.173
Reading #10th Centile (n=105) 42.9 (5.0) 43.2 (7.2) 0.837 44.0 (7.5) 42.3 (8.6) 0.473 1.0 (6.5) 20.9 (8.2) 0.187
{T scores have a mean of 50, sd = 10 and are derived from the British Ability Scales II.13.
doi:10.1371/journal.pone.0043909.t006
Figure 3. Change in working memory scores (recall of digits forward) between baseline and post-intervention.
doi:10.1371/journal.pone.0043909.g003
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time such problems can become compounded and the life chances
of these children further compromised [11]. These findings clearly
require replication, but we suggest that future studies should adopt
a similar focus on the most vulnerable groups within the general
population, ideally using additional measures to assess the relative
costs and benefits of this kind of dietary supplementation.
Figure 4. Change in working memory scores (recall of digit backwards) between baseline and post-intervention.
doi:10.1371/journal.pone.0043909.g004
Table 7. Standardized* Behavior Scores - Parent rated{ (intention to treat), means (sd).
Baseline Post-Intervention Change Score
Active
(n =180) Placebo (n =182)
Active
(n=180) Placebo (n=182)
Active
(n=180) Placebo (n=182) P
Oppositional 57.7 (12.0) 55.4 (9.5) 54.4 (10.8) 55.0 (9.6) 23.2 (10.1) 20.4 (8.1) 0.004
Cognitive Problems 59.7 (10.4) 57.7 (9.6) 56.0 (9.2) 55.7 (9.4) 23.7 (8.5) 22.0 (7.6) 0.055
Hyperactivity 54.1 (8.9) 53.5 (9.0) 51.2 (8.6) 52.2 (7.8) 22.9 (7.2) 21.2 (7.1) 0.007
Anxiety 51.7 (10.0) 51.7 (8.9) 47.9 (7.6) 49.9 (9.2) 23.8 (8.5) 21.8 (8.9) 0.074
Perfectionism 48.0 (8.3) 48.6 (8.4) 46.1 (6.9) 47.3 (7.7) 21.9 (6.9) 21.4 (7.4) 0.333
Social Problems 55.9 (11.6) 54.8 (10.7) 52.9 (9.8) 53.2 (10.4) 23.0 (10.0) 21.6 (10.8) 0.164
Psychosomatic 54.4 (10.7) 55.9 (11.5) 50.4 (9.4) 53.0 (10.7) 24.0 (10.2) 22.8 (11.2) 0.168
ADHD Index 58.2 (10.7) 56.7 (9.8) 53.7 (9.5) 54.1 (9.7) 24.5 (8.9) 22.6 (7.4) 0.042
Global Restless-Impulsive 57.6 (10.0) 55.8 (9.4) 52.8 (9.8) 53.6 (9.6) 24.8 (8.6) 22.3 (8.2) 0.001
Global Emotional Lability 54.7 (11.3) 53.2 (9.9) 51.5 (10.8) 53.0 (9.7) 23.1 (9.5) 20.2 (9.3) 0.001
Global Index Total 57.2 (10.5) 55.4 (9.6) 52.9 (10.2) 53.7 (9.5) 24.3 (8.8) 21.8 (8.2) 0.001
DSM-IV Inattention 56.7 (10.2) 54.7 (9.3) 53.5 (9.3) 52.9 (9.4) 23.2 (8.3) 21.8 (7.5) 0.087
DSM-IV Hyperactive-
Impulsive
57.2 (10.5) 56.3 (10.5) 53.4 (10.0) 54.0 (9.6) 23.8 (8.3) 22.2 (8.2) 0.021
DSM-IV Total ADHD 57.4 (10.3) 56.1 (9.4) 53.6 (9.7) 54.0 (9.5) 23.8 (8.1) 22.1 (7.4) 0.031
*T scores have a mean of 50, sd = 10. For values above the mean, higher scores indicate more severe difficulties with behaviour and/or attention.
{Behaviour measures are derived from the Conners’ Teacher Rating Scale.15
doi:10.1371/journal.pone.0043909.t007
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Table 9. Standardized* Behavior Scores - Teacher rated{ (intention to treat), means (sd).
Baseline Post-Intervention Change Score
Active
(n =180)
Placebo
(n =182)
Active
(n =180)
Placebo
(n =182)
Active
(n=180)
Placebo
(n=182) P
Oppositional 53.7 (12.0) 56.0 (13.8) 52.7 (12.1) 53.8 (11.5) 21.1 (10.6) 22.2 (10.7) 0.701
Cognitive Problems 61.7 (9.2) 61.4 (8.6) 60.0 (8.7) 60.0 (8.0) 21.7 (7.7) 21.4 (8.5) 0.765
Hyperactivity 53.0 (10.3) 53.2 (10.5) 52.4 (9.5) 51.1 (9.0) 20.6 (7.3) 22.1 (9.2) 0.175
Anxiety 57.0 (10.6) 57.5 (12.9) 54.7 (11.1) 54.7 (10.9) 22.3 (10.6) 22.8 (11.4) 0.584
Perfectionism 48.0 (8.5) 47.6 (7.6) 48.2 (7.8) 46.7 (6.5) 0.2 (6.5) 20.8 (7.4) 0.033
Social Problems 53.3 (10.2) 54.1 (11.0) 52.4 (9.5) 52.5 (9.9) 20.9 (9.0) 21.6 (9.8) 0.324
ADHD Index 55.8 (10.7) 55.9 (10.2) 53.8 (9.9) 54.9 (8.9) 22.1 (8.2) 21.0 (9.2) 0.134
Global Restless-Impulsive 56.0 (11.1) 55.8 (10.4) 54.3 (10.6) 54.3 (9.2) 21.7 (8.6) 21.4 (9.5) 0.714
Global Emotional-Lability 52.1 (11.0) 53.8 (13.4) 51.2 (10.2) 51.5 (10.7) 20.9 (10.8) 22.3 (11.2) 0.901
Global Index Total 55.3 (11.2) 55.9 (11.4) 53.7 (10.7) 54.4 (9.6) 21.5 (9.1) 21.5 (9.8) 0.569
DSM-IV Inattention 57.7 (9.8) 58.4 (9.5) 56.0 (9.8) 56.2 (8.8) 21.7 (8.2) 22.2 (9.1) 0.651
DSM-IV Hyperactive-Impulsive 52.3 (10.7) 52.0 (10.2) 50.8 (9.5) 50.2 (8.9) 21.5 (7.7) 21.8 (8.7) 0.729
DSM-IV Total ADHD 55.8 (9.9) 56.3 (9.4) 54.3 (9.6) 54.3 (8.2) 21.5 (7.5) 22.1 (8.6) 0.821
*T scores have a mean of 50, sd = 10. For values above the mean, higher scores indicate more severe difficulties with behaviour and/or attention.
{Behavior measures are derived from the Conners’ Teacher Rating Scale.15
doi:10.1371/journal.pone.0043909.t009
Table 8. Standardized* Behavior Scores - Parent rated{ (per protocol), means (sd).
Baseline Post-Intervention Change Score
Active
(n =148)
Placebo
(n =147)
Active
(n =145)
Placebo
(n =148)
Active (
n=121)
Placebo
(n=128) P
Oppositional 58.0 (13.2) 55.8 (10.6) 55.0 (11.9) 55.3 (10.6) 22.1 (8.9) 20.3 (6.8) 0.117
Cognitive Problems 60.3 (11.4) 58.1 (10.7) 56.2 (10.2) 55.6 (10.5) 23.46 (7.9) 22.61 (6.5) 0.246
Hyperactivity 54.6 (9.8) 54.0 (9.9) 51.8 (9.5) 52.5 (8.6) 22.45 (6.7) 21.32 (5.9) 0.073
Anxiety 52.2 (11.0) 52.1 (9.9) 48.3 (8.4) 50.6 (10.1) 24.1 (8.5) 22.0 (7.7) 0.052
Perfectionism 48.4 (9.2) 49.3 (9.2) 46.7 (7.6) 47.8 (8.5) 22.0 (6.7) 21.6 (7.1) 0.459
Social Problems 56.7 (12.7) 55.7 (11.8) 53.6 (10.8) 53.9 (11.4) 22.4 (9.4) 21.4 (9.7) 0.522
Psychosomatic 54.7 (11.8) 56.5 (12.7) 51.0 (10.4) 53.7 (11.8) 23.9 (9.9) 23.0 (10.2) 0.362
ADHD Index 58.6 (11.8) 56.8 (10.8) 54.1 (10.5) 54.3 (10.8) 23.9 (7.8) 22.6 (6.2) 0.073
Global Restless-Impulsive 57.7 (11.1) 56.0 (10.5) 53.5 (10.8) 53.9 (10.7) 24.1 (7.5) 22.2 (6.8) 0.018
Global Emotional Lability 55.3 (12.4) 53.4 (11.0) 52.4 (11.9) 53.2 (10.7) 22.4 (7.7) 21.0 (8.3) 0.028
Global Index Total 57.6 (11.5) 55.8 (10.7) 53.6 (11.3) 54.1 (10.5) 23.8 (7.1) 22.0 (6.8) 0.018
DSM-IV Inattention 57.111.2) 55.1 (10.4) 53.810.4) 53.3 (10.3) 22.75 (7.4) 22.12 (6.1) 0.104
DSM-IV
Hyperactive-Impulsive
57.6 (11.5) 56.8 (11.6) 53.9 (11.1) 54.5 (10.6) 23.1 (7.5) 22.3 (6.4) 0.425
DSM-IV Total ADHD 57.9 (11.3) 56.3 (10.5) 54.2 (10.7) 54.3 (10.5) 23.1 (7.1) 22.3 (5.9) 0.219
*T scores have a mean of 50, sd = 10. For values above the mean, higher scores indicate more severe difficulties with behaviour and/or attention.
{Behaviour measures are derived from the Conners’ Teacher Rating Scale.15
doi:10.1371/journal.pone.0043909.t008
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